Rome Michael E 4
4 · Kinnate Biopharma Inc. · Filed Apr 5, 2024
Insider Transaction Report
Form 4
Rome Michael E
Director
Transactions
- Disposition to Issuer
Stock Option (right to buy)
2024-04-03−20,250→ 0 totalExercise: $8.38Exp: 2032-06-13→ Common Stock (20,250 underlying) - Disposition to Issuer
Stock Option (right to buy)
2024-04-03−40,501→ 0 totalExercise: $20.00Exp: 2030-12-02→ Common Stock (40,501 underlying)
Footnotes (1)
- [F1]This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount.